Newsroom - CAMP4
Aug 27, 2024 · October 1, 2024. CAMP4 Enters Strategic Research Collaboration to Advance Novel Regulatory RNA-Targeting Medicines for Rare Genetic Conditions. September 17, 2024. CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders. August 27, 2024.
CAMP4 is latest to eye IPO, while Upstream spells out $182M plan
Oct 7, 2024 · RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its own ambitions at $182 million.
Camp4 stock gains after earning bullish views (CAMP:NASDAQ)
Nov 5, 2024 · Recently IPO'ed biotech Camp4 Therapeutics (NASDAQ: CAMP) recorded its best intraday gains since its public debut in October as J.P. Morgan and Piper Sandler launched its coverage with Overweight ...
CAMP4 Secures $100 Million Series B Financing to Accelerate …
Jul 20, 2022 · CAMP4’s RNA Actuating Platform (RAP™) maps regRNAs associated with every protein-coding gene in any cell type, and its programmable antisense oligonucleotide (ASO) therapeutics target the controlling regRNAs to upregulate gene expression to treat disease.
CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Price, News…
Find the latest CAMP4 THERAPEUTICS CORPORATION (CAMP) stock quote, history, news and other vital information to help you with your stock trading and investing.
CAMP4 THERAPEUTICS CORPORATION (CAMP) Latest Stock News …
Get the latest CAMP4 THERAPEUTICS CORPORATION (CAMP) stock news and headlines to help you in your trading and investing decisions.
CAMP4 Therapeutics Announces Dosing of First Participant in …
CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corp., a clinical-stage biotechnology company harnessing the power of regulatory RNA to restore healthy gene expression,...
CAMP4 Raises $45 Million to Usher in a New Era of Programmable ...
Jun 15, 2021 · Biotech company CAMP4 Therapeutics announcing new financing and next phase of its scientific strategy harnessing the power of RNA to upregulate genes.
Camp4 Therapeutics initiated with an Outperform at Leerink
Nov 5, 2024 · Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead program in urea cycle disorders, offers a pathway to ...
Kaiser Permanente-backed biopharma CAMP4 raises $75 mln in …
Oct 10 (Reuters) - CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente raised $75 million on Thursday in its U.S. initial public offering. CAMP4 sold 6.82...